

A case of Japanese pediatric cutaneous mastocytosis with disparate clinical classifications of maculopapular cutaneous mastocytosis and mastocytoma

Dear Editor,

Cutaneous mastocytosis (CM) is a disease in which mast cells localized in the cutaneous and extracutaneous tissue hyperproliferate¹.

Herein, we described a case of a Japanese pediatric patient with two disparate clinical features of CM and a D816V mutation. This study was approved by Tokyo Medical University Ethics Committee





FIGURE 1 Clinical features and dermoscopic findings of cutaneous mastocytosis. A, Face and trunk; B, back; C, dermoscopic finding of the mastocytoma of the back; and D, dermoscopic findings of the maculopapular cutaneous mastocytosis of the trunk

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. *Journal of Cutaneous Immunology and Allergy* published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society for Cutaneous Immunology and Allergy

FIGURE 2 Histological observations of the mastocytoma and maculopapular cutaneous mastocytosis. A, Mastocytoma at lower magnification (hematoxylin and eosin staining, scale bar: 500 μ m). B, Mastocytoma at higher magnification (hematoxylin and eosin staining, scale bar: 100 μ m). C, Maculopapular cutaneous mastocytosis at lower magnification (hematoxylin and eosin staining, scale bar: 500 μ m). D, Maculopapular cutaneous mastocytosis at higher magnification (hematoxylin and eosin staining, scale bar: 100 μ m). E, Mastocytoma at higher magnification (Toluidin blue staining, scale bar: 100 μ m). F, Maculopapular cutaneous mastocytosis at higher magnification (Toluidin blue staining, scale bar: 500 μ m)



(No. T2019-0160). A 4-month-old Japanese male patient was born with two nodules on the back and multiple flat macules distributed over the entire body. The clinical examination revealed two lesions that 1.5-cm reddish-brown nodules on the upper and left back and multiple, flat, brownish macules scattered over the entire body (Figure 1A,B). Both types of lesion were positive for Darier's sign. Dermoscopy revealed a pattern of yellowish-orange dots in the two nodules and fine brown reticular lines in the multiple flat macules (Figure 1C,D). A skin biopsy of a nodule and macule was performed. Histology of the nodule demonstrated the presence of ballooned cells in the dermis (Figure 2A,B) and that of the macule likewise demonstrated the presence of ballooned cells in the upper dermis around the vessels (Figure 2C,D). Toluidine blue showed metachromatic staining (Figure 2E,F) in the ballooned cells. Based on these findings, the preliminary diagnosis of mastocytoma and maculopapular cutaneous mastocytosis (MCM) was made. Direct sequencing of mRNA isolated from the mastocytoma and MCM was analyzed mutations of the *KIT* gene in exons 9, 11, and 17, including five hot spot areas (codons 509, 522, 560, 816, and 820). This case was diagnosed both the mastocytoma and MCM contained

KIT D816V mutations. The patient experienced no developmental abnormalities, and anaphylaxis due to UV and temperature were denied. A blood test was normal, and splenomegaly was denied. At a follow-up examination six months after receiving H₁ receptor blockers, the patient denied organomegaly and severe symptoms, and subsequent follow-up visits to the hospital at intervals of six months were scheduled.

The prognosis of CM is better in pediatric patients than in adults. In approximately 70% to 80% of affected children, the disease resolves by adulthood. About 20%–30% of pediatric cases of CM involve a *KIT* D816V mutation². In pediatric CM, the risk of anaphylaxis and aggressive disease is considered to be low. Previous studies have reported three similar cases of the co-occurrence of MCM and mastocytoma³, all of which harbored a *KIT* gene mutation in exon 9 although in the present case the mutation was detected in exon 17. The present study is the first to report a case of pediatric CM with a *KIT* D816V mutation with the co-occurrence of the two clinical features of nodules and macular plaques. Recent research has revealed that the *KIT* D816V mutation in mastocytosis patients may be a predictor for persistent factors⁴. The relations two disparate


clinical features of CM and D816V mutation cannot explain now. And two disparate of CM is very rare. Thus, long-term follow-up of affected children is necessary, and prospective studies evaluating the prognostic value of sequencing *KIT*⁵ are warranted.

ACKNOWLEDGMENT

The patients in this manuscript have given written informed consent to publication of their case details.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Tomonobu Ito 

Chizu Egusa

Tatsuo Maeda

Harutaka Seshimo

Yukari Okubo

Kazutoshi Harada

*Department of Dermatology, Tokyo Medical University, Tokyo,
Japan*

Correspondence

Tomonobu Ito, Department of Dermatology, Tokyo Medical
University, 6-7-1 Nishi-Shinjuku, Shinjuku-ku Tokyo
160-0023, Japan.
Email: tomonobu@tokyo-med.ac.jp

ORCID

Tomonobu Ito  <https://orcid.org/0000-0003-0428-6280>

REFERENCES

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127:2391–405.
2. Bibi S, Langenfeld F, Jeanningros S, Brenet F, Soucie E, Hermine O, et al. Molecular defects in mastocytosis: KIT and beyond KIT. *Immunol Allergy Clin North Am*. 2014;34:239–62.
3. Arase N, Wataya-Kaneda M, Murota H, et al. Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wild-type KIT patients. *J Dermatol*. 2020;47:426–9.
4. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. *J Allergy Clin Immunol*. 2016;137:35–45.
5. Méni C, Bruneau J, Georgin-Lavialle S, Saché LE, de Peuffeilhoux L, Damaj G, et al. Paediatric mastocytosis: a systematic review of 1747 cases. *Br J Dermatol*. 2015;172:642–51.